Published in World J Gastroenterol on June 07, 2012
ERCC1 Can Be a Prognostic Factor in Hilar Cholangiocarcinoma and Extrahepatic Bile Duct Cancer, But Not in Intrahepatic Cholangiocarcinoma. Cancer Res Treat (2013) 0.80
Is There a Role for Adjuvant Therapy in R0 Resected Gallbladder Cancer?: A Propensity Score-Matched Analysis. Cancer Res Treat (2016) 0.75
The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection. Chin J Cancer (2017) 0.75
Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med (2010) 15.71
Biliary tract cancers. N Engl J Med (1999) 6.36
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol (1996) 4.00
Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. J Clin Oncol (2008) 3.44
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg (1997) 2.53
Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg (2007) 2.48
Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol (2009) 2.17
Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol (2011) 2.13
Improved survival in resected biliary malignancies. Surgery (2002) 1.67
AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: By the AFC-IHCC-2009 study group. Cancer (2010) 1.44
Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. Int J Radiat Oncol Biol Phys (2009) 1.34
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct. Int J Radiat Oncol Biol Phys (2007) 1.31
Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys (2002) 1.31
Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment. Ann Surg (2011) 1.24
Adjuvant chemoradiation therapy in gallbladder cancer. J Surg Oncol (2010) 1.20
Biliary tract cancer treatment: results from the Biliary Tract Cancer Statistics Registry in Japan. J Hepatobiliary Pancreat Surg (2002) 1.17
Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg (2009) 1.15
Extrahepatic bile duct cancers: surgery alone versus surgery plus postoperative radiation therapy. Int J Radiat Oncol Biol Phys (2009) 1.15
Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Radiat Oncol (2011) 1.10
Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg (2001) 1.10
Extrahepatic bile duct adenocarcinoma: patients at high-risk for local recurrence treated with surgery and adjuvant chemoradiation have an equivalent overall survival to patients with standard-risk treated with surgery alone. Ann Surg Oncol (2008) 1.09
Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg (2009) 1.09
Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma. Br J Cancer (2011) 1.09
Cholangiocarcinoma: the impact of tumor location and treatment strategy on outcome. Am J Clin Oncol (2003) 1.07
Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys (2006) 1.06
Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys (2007) 1.03
Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis. Int J Radiat Oncol Biol Phys (2010) 0.99
Prognostic analysis of surgical treatment of peripheral cholangiocarcinoma: two decades of experience at Chang Gung Memorial Hospital. World J Gastroenterol (2005) 0.98
Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand J Gastroenterol (2011) 0.96
Metastatic lymph nodes in hilar cholangiocarcinoma: does size matter? HPB (Oxford) (2011) 0.95
Predictors of long-term survival in patients with gallbladder cancer. J Gastrointest Surg (2006) 0.95
Postoperative chemoradiotherapy for extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys (2010) 0.95
Assessment of the nodal status in ampullary carcinoma: the number of positive lymph nodes versus the lymph node ratio. World J Surg (2011) 0.94
High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer. J Int Med Res (2011) 0.93
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience. Am J Clin Oncol (2012) 0.93
The prognostic importance of lymphovascular invasion in cholangiocarcinoma above the cystic duct: a new selection criterion for adjuvant therapy? HPB (Oxford) (2011) 0.92
Lymphadenectomy in the staging and treatment of intrahepatic cholangiocarcinoma: a population-based study using the National Cancer Institute SEER database. HPB (Oxford) (2011) 0.91
Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig Surg (2011) 0.91
Indication for postoperative adjuvant therapy in biliary carcinoma based on analysis of recurrence and survival after surgical resection. Dig Dis Sci (2008) 0.90
Radiation therapy, chemotherapy and chemoradiation in hilar cholangiocarcinoma. HPB (Oxford) (2005) 0.89
The influence of prognostic factors and adjuvant chemoradiation on survival after pancreaticoduodenectomy for ampullary carcinoma. J Gastrointest Surg (2011) 0.89
Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma. Int J Clin Exp Pathol (2011) 0.88
Surgical outcomes and prognostic factors for ampulla of Vater cancer. Scand J Surg (2011) 0.88
Adenocarcinoma of the ampulla of Vater: T-stage, chromosome 17p allelic loss, and extended pancreaticoduodenectomy are relevant prognostic factors. J Gastrointest Surg (2007) 0.88
Adjuvant radio-chemotherapy for extrahepatic biliary tract cancers. BMC Cancer (2011) 0.87
Current status of intrahepatic cholangiocarcinoma. World J Gastroenterol (2008) 0.87
Prognostic factors of patients with advanced gallbladder carcinoma following aggressive surgical resection. J Gastrointest Surg (2011) 0.86
Medical history and the risk of biliary tract cancers in Shanghai, China: implications for a role of inflammation. Cancer Causes Control (2011) 0.86
Modification and implementation of NCCN guidelines on hepatobiliary cancers in the Middle East and North Africa region. J Natl Compr Canc Netw (2010) 0.84
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2010) 0.84
Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev (2009) 0.84
Correlation between MMP1-PAR1 axis and clinical outcome of primary gallbladder carcinoma. Jpn J Clin Oncol (2011) 0.83
Prognostic significance of lymph node ratio after resection of peri-hilar cholangiocarcinoma. HPB (Oxford) (2011) 0.82
Prognostic factors after pancreatoduodenectomy for distal bile duct cancer. Am Surg (2011) 0.81
Outcome of adjuvant therapy for gallbladder cancer. Oncology (2010) 0.81
Tumor budding and dedifferentiation in gallbladder carcinoma: potential for the prognostic factors in T2 lesions. Virchows Arch (2011) 0.80
Adjuvant chemotherapy for resectable biliary tract cancer: current status and future direction. J Hepatobiliary Pancreat Sci (2012) 0.79
Adjuvant therapy for gallbladder and bile duct cancers: retrospective comparative study. J BUON (2011) 0.79
Prognostic impact of vascular endothelial growth factor-A expression in resected gallbladder carcinoma. Tumour Biol (2011) 0.79
Prognostic impact of histological blood vessel invasion in patients with ampullary adenocarcinoma. Hepatogastroenterology (2011) 0.79
Adjuvant radio-chemotherapy after extended or simple cholecystectomy in gallbladder cancer. Clin Transl Oncol (2011) 0.77
Morphology, TNM staging and survival with Pancreatico-duodenectomy specimens received at Shaukat Khanum Memorial Cancer Hospital and Research Centre, Pakistan. Asian Pac J Cancer Prev (2011) 0.76
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med (2013) 16.24
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet (2009) 4.25
Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med (2011) 3.59
Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol (2006) 2.81
Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol (2003) 2.44
Meningioma. Crit Rev Oncol Hematol (2008) 2.10
Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study. Int J Radiat Oncol Biol Phys (2013) 2.04
Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer (2009) 1.82
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol (2006) 1.77
MATILDE chemotherapy regimen for primary CNS lymphoma: results at a median follow-up of 12 years. Neurology (2014) 1.58
Glioblastoma in adults. Crit Rev Oncol Hematol (2008) 1.54
The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma. Cancer Res (2008) 1.30
High-dose chemotherapy supported by autologous stem cell transplantation in patients with primary central nervous system lymphoma: facts and opinions. Leuk Lymphoma (2008) 1.29
Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer (2002) 1.20
Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol (2007) 1.17
Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer (2007) 1.14
Feasibility and safety of EUS-guided cryothermal ablation in patients with locally advanced pancreatic cancer. Gastrointest Endosc (2012) 1.07
Informed consent as an ethical requirement in clinical trials: an old, but still unresolved issue. An observational study to evaluate patient's informed consent comprehension. J Med Ethics (2013) 1.07
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol (2004) 1.05
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. Virchows Arch (2004) 1.05
Adult Wilms' tumor: A monoinstitutional experience and a review of the literature. Cancer (2004) 1.05
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases. Eur J Endocrinol (2010) 1.04
Target delineation in post-operative radiotherapy of brain gliomas: interobserver variability and impact of image registration of MR(pre-operative) images on treatment planning CT scans. Radiother Oncol (2005) 1.03
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. Cancer (2005) 1.01
Oligodendroglioma. Crit Rev Oncol Hematol (2008) 1.01
Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol (2008) 1.00
First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol (2004) 1.00
Adult neuroectodermal tumors of posterior fossa (medulloblastoma) and of supratentorial sites (stPNET). Crit Rev Oncol Hematol (2009) 0.99
Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol (2006) 0.99
Second-line therapy in advanced biliary tract cancer: what should be the standard? Crit Rev Oncol Hematol (2013) 0.96
Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br J Haematol (2004) 0.96
Primary central nervous system lymphoma. Crit Rev Oncol Hematol (2007) 0.93
Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies. J Oncol (2009) 0.91
Contrast enhanced 4D-CT imaging for target volume definition in pancreatic ductal adenocarcinoma. Radiother Oncol (2008) 0.90
Treatment approaches for primary CNS lymphomas. Expert Opin Pharmacother (2010) 0.89
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer. Anticancer Res (2010) 0.87
Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. Pancreatology (2006) 0.87
Is withdrawal of consolidation radiotherapy an evidence-based strategy in primary central nervous system lymphomas? J Clin Oncol (2004) 0.87
Maintenance sunitinib or observation in metastatic pancreatic adenocarcinoma: a phase II randomised trial. Eur J Cancer (2013) 0.87
The role of CXCR4 in highly malignant human gliomas biology: current knowledge and future directions. Glia (2014) 0.86
Neoadjuvant therapy in resectable pancreatic cancer: a critical review. Cancer Treat Rev (2012) 0.86
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma. Cancer (2010) 0.85
Mechanisms, indications and results of salvage systemic therapy for sporadic and von Hippel-Lindau related hemangioblastomas of the central nervous system. Crit Rev Oncol Hematol (2012) 0.85
Solitary clival plasmocytomas: Misleading clinical and radiological features of a rare pathology with a specific biological behaviour. Acta Neurochir (Wien) (2013) 0.85
Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. Tumour Biol (2012) 0.85
Antiangiogenic strategies in breast cancer management. Crit Rev Oncol Hematol (2010) 0.84
Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF. J Oncol (2010) 0.84
Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing? World J Gastroenterol (2010) 0.83
Salvage therapy with mitomycin and ifosfamide in patients with gemcitabine-resistant metastatic pancreatic cancer: a phase II trial. Chemotherapy (2011) 0.83
Time course of hypothalamic-pituitary deficiency in adults receiving cranial radiotherapy for primary extrasellar brain tumors. Radiother Oncol (2011) 0.83
Consolidation radiotherapy in primary central nervous system lymphomas: impact on outcome of different fields and doses in patients in complete remission after upfront chemotherapy. Int J Radiat Oncol Biol Phys (2010) 0.83
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case? J Thorac Oncol (2008) 0.82
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). Cancer Chemother Pharmacol (2011) 0.82
Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol (2012) 0.82
Planning design of locally advanced pancreatic carcinoma using 4DCT and IMRT/IGRT technologies. Acta Oncol (2010) 0.82
Chemotherapy-induced anemia and oncologist perception on treatment: results of a web-based survey. Tumori (2013) 0.82
Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin North Am (2005) 0.82
Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer: XPD-Lys751Gln polymorphism strikes back. Int J Cancer (2013) 0.82
Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy. Pharmacogenomics (2011) 0.81
Amelanotic melanoma in a child with oculocutaneous albinism. Med Pediatr Oncol (2003) 0.81
Dosimetric and clinical predictors of toxicity following combined chemotherapy and moderately hypofractionated rotational radiotherapy of locally advanced pancreatic adenocarcinoma. Radiother Oncol (2013) 0.80
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Ann Surg Oncol (2012) 0.79
Preoperative chemotherapy does not adversely affect pancreatic structure and short-term outcome after pancreatectomy. J Gastrointest Surg (2012) 0.79
Questions and answers in the management of primary central nervous system and ocular lymphomas. Haematologica (2003) 0.79
Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination. Oncologist (2011) 0.79
No association between polyomaviruses and primary central nervous system lymphomas of HIV-seronegative and HIV-positive patients. Cancer Epidemiol Biomarkers Prev (2004) 0.78
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? Anticancer Drugs (2010) 0.78
Rhabdomyosarcoma of the head and neck region: experience at the pediatric unit of the Istituto Nazionale Tumori, Milan. J Otolaryngol (2006) 0.78
Clinical signature and pathogenetic factors of diabetes associated with pancreas disease (T3cDM): a prospective observational study in surgical patients. Acta Diabetol (2014) 0.78
Whole-brain radiotherapy in primary CNS lymphoma. Lancet Oncol (2011) 0.77
Role of taxanes in pancreatic cancer. World J Gastroenterol (2012) 0.77
A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients. Pharmacogenomics (2014) 0.77
Current uses of radiation therapy in patients with primary CNS lymphoma. Expert Rev Anticancer Ther (2013) 0.76
Primary CNS lymphomas prognosis. J Clin Oncol (2007) 0.75
Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer. Br J Cancer (2016) 0.75
Establishing a prognostic score for primary CNS lymphomas. Int J Radiat Oncol Biol Phys (2005) 0.75
Current therapeutic approaches to primary CNS lymphoma. Expert Rev Neurother (2003) 0.75
New therapies for pancreatic cancer: current standard. JOP (2007) 0.75
Treatment trends in metastatic pancreatic cancer patients: Is it time to change? Dig Liver Dis (2010) 0.75